Funder: National Institutes of Health
Due Dates: April 4, 2025 | October 3, 2025 | December 9, 2025 (final closing)
Funding Amounts: Up to $150,000 per year (direct costs), max 3 years; ~17 awards; total program funding $4.2M in FY26.
Summary: Supports early-stage development of innovative molecular or cellular analysis technologies to advance basic or clinical cancer research; clinical trials are not allowed.
Key Information: Applications must focus on technology innovation (not hypothesis-driven research); projects must include quantitative performance measures.